Similarly, treatment with TRC105 led to a significant decline in the number of Tregs in patients with metastatic urothelial carcinoma and castration-resistant prostate cancer [174,175], making Tregs a novel target for ENG targeted therapy. This evidence concerns the gene ENG and Familial prostate cancer.